Business
GHO Capital Sells VISUfarma to Lupin
London, Mumbai, 29 September, 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is delighted to announce the sale of VISUfarma, a specialty pharmaceutical company focused on ophthalmology, to global pharma major Lupin Limited (Lupin).VISUfarma was created by GHO Capital in 2016 by combining the founder-owned Italian VISUfarma with the European commercial operations of Nicox S.A. Since its initial investment as part
About this update from Nicox Sa
[{"type":"image","alt":"GHO Capital","displaySize":"","headline":null,"caption":"GHO Capital","className":"","disableSlideshowImg":false,"size":{"original":{"width":225,"height":225,"url":"https://media.zenfs.com/en/globenewswire.com/7367e47c438ea334789158ceb1bf9bdc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cOn9YJvOCRKFsTq.4fr1YQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7367e47c438ea334789158ceb1bf9bdc","width":225,"height":225},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/cOn9YJvOCRKFsTq.4fr1YQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7367e47c438ea334789158ceb1bf9bdc","width":225,"height":225}},"lazy":false},{"type":"text","content":"London, Mumbai, 29 September, 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is delighted to announce the sale of VISUfarma, a specialty pharmaceutical company focused on ophthalmology, to global pharma major Lupin Limited (Lupin).","length":315,"tagName":"p"},{"type":"text","content":"VISUfarma was created by GHO Capital in 2016 by combining the founder-owned Italian VISUfarma with the European commercial operations of Nicox S.A. Since its initial investment as part of Fund I, GHO has grown the business substantially into a pan-European leader of ophthalmology pharmaceuticals.","length":297,"tagName":"p"},{"type":"text","content":"Lupin’s wholly owned subsidiary, Nanomi B.V. has signed a definitive agreement for the acquisition, which is projected to close by the end of 2025, subject to certain closing conditions. The acquisition of VISUfarma, with its broad portfolio of innovative eye health products and established commercial infrastructure, aligns with Lupin’s strategy to expand its European business and footprint and to advance the company’s global specialty franchise.","length":450,"tagName":"p"},{"type":"text","content":"VISUfarma's established European operations will provide market expansion opportunities, direct presence and further business diversification across major European countries, including Italy, the UK, Spain, Germany and France. In addition, VISUfarma’s broad portfolio of 60+ branded ophthalmology products will present growth opportunities to accelerate Lupin's expansion into the spec...